

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Transplantation</b>				
Graft-versus-host-disease (GvHD)	T cell receptor (TCR)	<p>Studies in cell culture and in mice suggest that CD4<sup>+</sup>/CD5<sup>+</sup> T regulatory cells (Tregs) engineered to express TCR could be useful for treating GvHD. In immunocompetent mice, TCR-transduced Tregs plus short-term immunosuppressive therapy improved survival of mismatched heart grafts compared with that seen using immunosuppressives alone or immunosuppressives plus normal Tregs. TCR-transduced Tregs acquired an indirect allospecificity while retaining their direct allospecificity. Next steps include investigating alternative methods for producing human Tregs with indirect allospecificity without using TCR gene transfer.</p> <p><i>SciBX</i> 1(39); doi:10.1038/scibx.2008.955 Published online Oct. 30, 2008</p>	Unpatented; unlicensed	<p>Tsang, J. <i>et al. J. Clin. Invest.</i>; published online Oct. 9, 2008; doi:10.1172/JCI33185  <b>Contact:</b> Robert Lechler, King's College London, London, U.K.                      e-mail: <a href="mailto:robert.lechler@kcl.ac.uk">robert.lechler@kcl.ac.uk</a></p>